Enlarging the NSAIDs family: Ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents

Current Medicinal Chemistry

Volumn 18, Issue 10, 2011, Pages 1540-1554

  Biava, M ^a   Porretta, G C ^a   Poce, G ^a   Battilocchio, C ^a   Botta, M ^b   Manetti, F ^b   Rovini, M ^b   Cappelli, A ^b   Sautebin, L ^c   Rossi, A ^c   Pergola, C ^d   Ghelardini, C ^e   Galeotti, N ^e   Makovec, F ^f   Giordani, A ^f   Anzellotti, P ^g   Tacconelli, S ^g   Patrignani, P ^g   Anzini, M ^b,h  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF FLORENCE   (Italy)

^f Rotta Research Laboratorium   (Italy)

^g UNIVERSITY OF CHIETI   (Italy)

^h European Research Centre for Drug Discovery and Development   (Italy)

Author keywords

Analgesic agents; Anti inflammatory agents; Celecoxib; COX 1 inhibitors; COX 2 inhibitors; Coxibs; Pyrrole derivatives; t NSAIDs

Indexed keywords

ANALGESIC AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ESTER DERIVATIVE; ETHER DERIVATIVE; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PYRROLE DERIVATIVE; ROFECOXIB; SULFONE DERIVATIVE; VALDECOXIB;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PAW EDEMA; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; THROMBOSIS;

EID: 79955005080     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795328364     Document Type: Article

References (63)

1. Burke, A.; Smyth, E.; FitzGerald, G.A. Analgesic-antipyretic agents: pharmacotherapy of gout. In: Goodman & Gilman's The Pharmacological Basis of Therapeutic; Brunton L.L., Lazo J.S., Parker K.L., editors. 11th edition. New York, NY: McGraw-Hill, 2006, 673-715.
2. Funk, C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science, 2001, 294, 1871-75. (Pubitemid 33101574)
3. Marnett, L.J.; Rowlinson, S.W.; Goodwin, D.C.; Kalgutkar, A.S.; Lanzo, C.A. Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition. J. Biol. Chem., 1999, 274, 22903-06.
4. Kulmacz, J.; Wang, L.H. Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and - 2. J. Biol. Chem., 1995, 270, 24019-23.
5. Ueno, N.; Murakami, M.; Tanioka, T; Fujimori, K.; Tanabe, T.; Urade, Y; Kudo, I. Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. J. Biol Chem., 2001, 276, 34918-27.
6. FitzGerald, G.A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug. Discov., 2003, 2, 879-90.
7. a) Xie, W.; Chipman, J.G.; Robertson, D.L.; Erikson, R.L.; Simmons, D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl Acad. Sci USA., 1991, 88, 2692-96; (Pubitemid 21916484)
8. b) Kujubu, D.A.; Herschman, H.R.; Dexamethasone inhibits mitogen induction of the T1s10 prostaglandin synthase/cyclooxygenase gene. J. Biol. Chem., 1992, 267, 7991-94;
9. c) O'Banion, M.K.; Winn, V.D.; Young, D.A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl Acad. Sci USA., 1992, 89, 4888-92.
10. Dixon, D.A.; Kaplan, C.D.; Mclntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. Post-transcriptional control of cyclooxygenase-2 gene expression: the role of the 3'-untranslated region. J. Biol. Chem., 2000, 275, 11750-57. (Pubitemid 30237739)
11. Simmons, L.; Botting, R.M.; Hla, T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev, 2004, 56, 387-437. (Pubitemid 39096597)
12. a) Rocca, B.; Spain, L.M.; Pure, E.; Langenbach, R.; Patrono, C.; FitzGerald, G.A. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J. Clin. Invest., 1999, 103, 1469-77; (Pubitemid 29535503)
13. b) Smith, W.L.; Langenbach, R. Why there are two cyclooxygenase isozymes. J. Clin. Invest., 2001, 107, 1491-49;
14. c) Yamagata, K.; Andreasson, K.I.; Kaufmann, W.E.; Barnes, C.A.; Worley, P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activityand glucocorticoids. Neuron, 1993, 11, 371-86. (Pubitemid 23250354)
15. d) Topper, J.N.; Cai, J.; Falb, D.; Gimbrone, M.A.Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 10417-22;
16. e) Ferreri, N.R.; An, S.J.; McGiff, J.C. Cyclooxygenase-2 expression and function in the medullary thick ascending limb. Am. J. Physiol., 1999, 277, F360-F368 (Pubitemid 29459648)
17. f) Harris, R.C.; Breyer, M.D. Physiological regulation of cyclooxygenase-2 in the kidney. Am. J. Physiol. Renal. Physiol., 2001, 281, F1-11.
18. Patrono, C.; Patrignani, P.; García Rodríguez, L.A. Cyclooxygenaseselective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J. Clin. Invest., 2001, 108(1),7-13. (Pubitemid 32634915)
19. a) Capone, M.L.; Tacconelli, S.; Di Francesco, L.; Sacchetti, A.; Sciulli, M.G.; Patrignani, P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat., 2007, 82(1-4), 85-94; (Pubitemid 44895440)
20. b) Tacconelli, S.; Capone, M.L.; Patrignani, P.; Clinical pharmacology of novel selective COX-2 inhibitors. Curr. Pharm. Des., 2004, 10(6), 589-601. (Pubitemid 38292386)
21. a) Patrignani, P.; Panara, M.R.; Greco, A.; Fusco, O.; Natoli, C.; Iacobelli, S.; Cipollone, F; Ganci, A.; Créminon, C.; Maclouf, J.; Patrono C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther., 1994, 271, 1705-12; (Pubitemid 24382690)
22. Patrono, C.; Ciabattoni, G.; Pinca, E.; Pugliese, F.; Castrucci, G.; De Salvo, A.; Satta, M.A.; Peskar, B.A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb. Res., 1980, 17, 317-27. (Pubitemid 10129020)
23. a) Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M.B.; Hawkey, C.J.; Hochberg, M.C.; Kvien, T.K.; Shnitzer, T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in atients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 2000, 343(21),1520-28;
24. Schnitzer, T.J.; Burmester, G.R.; Mysler, E.; Hochberg, M.C.; Doherty, M.; Ehrsam, E.; Gitton, X.; Krammer, G.; Mellein, B.; Matchaba, P.; Gimona, A.; Hawkey, C.J. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet., 2004, 364,665-74. (Pubitemid 39140622)
25. Kargman, S.; Charleson, S.; Cartwright, M.; Frank, J.; Riendeau, D.; Mancini, J.; Evans, J.; O'Neill, G.C.; Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996, 111,445-54. (Pubitemid 26256734)
26. a) Schmassmann, A.; Zoidl, G.; Peskar, B. M.; Waser, B.; Schmassmann-Suhijar, D.; Gebbers, J.O.; Reubi, J. C. Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and-2 knockout mice. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290(4), G747-56;
27. b) Shigeta, J.; Takahashi, S.; Okabe, S. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J. Pharmacol. Exp. Ther., 1998, 286, 1383-90; (Pubitemid 29135552)
28. c) Mizuno, H.; Akamatsu, T.; Kasuga, M. Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology, 1997, 112, 387-397; (Pubitemid 27078825)
29. d) Jones, M.K.; Wang, H.; Peskar, B.M.; Levin, E.; Itani, R.M.; Sarfeh, I.J.; Tarnawski, A.S. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: insight into mechanism and implications for cancer growth and ulcer healing. Nat. Med., 1999, 5, 1418-23.
30. Masso González, E.L.; Patrignani, P.; Tacconelli, S.; Rodríguez, L.A. Variability of risk of upper gastrointestinal bleeding among nonsteroidal antiinflammatory drugs. Arthritis Rheum., 2010 in press.
31. Cryer, B.; Feldman, M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-infl ammatory drugs. Am. J. Med., 1998, 104, 413-21. (Pubitemid 28274844)
32. García Rodríguez, L.A.; Tacconelli, S.; Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol., 2008, 52(20), 1628-36.
33. Di Francesco, L.; Totani, L.; Dovizio, M.; Piccol, A.; Di Francesco, A.; Salvatore, T.; Pandolci, A.; Evangelista, V.; Dercho, R.A.; Seta, F.; Patrignani P. Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells. Circ. Res., 2009, 104(4), 506-13.
34. Cheng, Y.; Wang, M.; Yu, Y; Lawson, J.; Funk, C.D.; Fitzgerald, G.A. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest., 2006, 116, 1391-99.
35. Arehart, E.; Stitham, J.; Asselbergs, F.W.; Douville, K.; MacKenzie, T.; Fetalvero, K.M.; Gleim, S.; Kasza, Z.; Rao, Y.; Martel, L.; Segel, S.; Robb, J.; Kaplan, A.; Simons, M.; Powell, R.J.; Moore, J.H.; Rimm, E.B.; Martin, K.A.; Hwa, J. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ. Res., 2008, 102, 986-93. (Pubitemid 351591551)
36. a) Grosser, T.; Fries, S.; FitzGerald, G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest., 2006, 116, 4-15; (Pubitemid 43121782)
37. b) Patrignani, P.; Capone, M.L.; Tacconelli, S. NSAIDs and cardiovascular disease. Heart, 2008, 94, 395-97. (Pubitemid 351441386)
38. Fries, S.; Grosser, T.; Price, T.S.; Lawson, J.; Kapoor, S.; DeMarco, S.; Pletcher, M.; Wiltshire, T.; FitzGerald G. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology, 2006, 130, 55-64. (Pubitemid 43049835)
39. a) Biava, M.; Porretta, G.C.; Cappelli, A.; Vomero, S.; Botta, M.; Manetti, F.; Giorni, G.; Sautebin, L.; Rossi, A.; Makovec, F.; Anzini, M. 1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and selective COX-2 inhibitors. J. Med. Chem., 2005, 48, 3428-32; (Pubitemid 40628060)
40. b) Biava, M.; Porretta, G.C.; Poce, G.; Supino, S.; Forli, S.; Rovini, M.; Cappelli, A.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Vivoli, E.; Makovec, F.; Anzellotti, P.; Patrignani, P.; Anzini, M. COX-2 inhibitors. 1,5-Diarylpyrrole-3-acetic esters with enhanced inhibitory activity toward COX-2 and improved COX-2/COX-1 selectivity. J. Med. Chem., 2007, 50, 5403-11; (Pubitemid 350064001)
41. c) Biava, M.; Porretta, G.C.; Poce, G.; Supino, S.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Norcini, M.; Makovec, F.; Anzellotti, P.; Cirilli, R.; Ferretti, R.; Gallinella, B.; La Torre, F.; Anzini, M.; Patrignani, P. Chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel antiinflammatory and analgesic agents. Synthesis, in vitro and in vivo biological evaluation and molecular docking simulations. Bioorg. Med. Chem., 2008, 16 (17), 8072-81;
42. d) Biava, M.; Cirilli, R.; Fares, V.; Ferretti, R.; Gallinella, B.; La Torre, F.; Poce, G.; Porretta, G. C.; Supino, S.; Villani, C. HPLC enantioseparation and absolute configuration of novel anti-inflammatory pyrrole derivatives. Chirality, 2008, 20, 775-80; (Pubitemid 351961766)
43. e) Anzini, M.; Rovini, M.; Cappelli, A.; Vomero, S.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Norcini, M.; Giordani, A.; Makovec, F.; Anzellotti, P.; Patrignani, P.; Biava, M. Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3- alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity. J. Med. Chem., 2008, 51, 4476-81
44. Cappelli, A.; Anzini, M.; Biava, M.; Makovec, F.; Giordani, A.; Caselli, G.; Rovati, L. C. 3-Substituted-1,5-diaryl-2-alkyl-pyrroles highly selective and orally effective COX-2 inhibitors. PCT Int. Appl. WO2008014821
45. g) Biava, M.; Porretta, G.C.; Poce, G.; Battilocchio, C.; Manetti, F.; Botta, M.; Forli, S.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Galeotti, N.; Makovec, F.; Giordani, A.; Anzellotti, P.; Patrignani P.; Anzini, M. Novel ester and acid derivatives of the 1,5-diarylpyrrole scaffold as anti-inflammatory and analgesic agents. Synthesis, in vitro and in vivo biological evaluation. J. Med. Chem., 2010, 53(2), 723-33.
46. Salter, E.A.; Wierzbicki, A.; Sperl, G.; Thompson, W. J. Molecular modeling study of COX-2 inhibition by diarylheterocycles and sulindac sulfide, J. MOl. Structure, 2001, 549, 111-121. (Pubitemid 32705840)
47. a) Jackson, P. F.; Bullington, J. L. Pyridinylimidazole based p38 MAP-Kinase inhibitors. Curr Top. Med. Chem., 2002, 2, 1011-20;
48. b) Sawyer, J. S.; Beight D. W.; Britt K. S.; Anderson, B. D.; Campbell, R. M.; Goodson, Jr. T.; Herron, D. K.; Li, H.Y.; McMillen, W. T.; Mort, N.; Parsons, S.; Smith, E. C. R.; Wagner, J. R.; Faming Zhanga, L. Y.; Yingling, J. M. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-b type I receptor kinase domain. Bioorg. Med. Chem. Lett., 2004, 14, 3581-84. (Pubitemid 38737172)
49. Liverton, N. J.; Butcher, J. W.; Claiborne, C. F.; Claremon, D. A.; Libby, B. E.; Nguyen, K. T.; Pitzenberger, S. M. Selnick, H. G.; Smith, G. R.; Tebben, A.; Vacca, J. P.; Varga, S. L.; Agarwal, L.; Dancheck, K.; Forsyth, A. J.; Fletcher, D. S.; Frantz, B.; Hanlon, W. A.; Harper, C. F.; Hofsess, S. J.; Kostura, M.; Lin, J.; Luell, S.; O'Neill, E. A.; Orevillo, C.J.; Pang, M.; Parsons, J.; Rolando, A.; Sahly, Y.; Visco, D.M.; O'Keefe, S. J. Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase. J. Med. Chem., 1999, 42, 2180-2190. (Pubitemid 29284237)
50. McIntyre, C.J.; Ponticello, G.S.; Liverton, N.J.; O'Keefe, S.J.; Edward A. O'Neill, E.A.; Margaret Pang, M.; Schwartzb, C.D.; Claremona, D.A. Pyridazine Based Inhibitors of p38 MAPK. Bioorg. Med. Chem. Lett., 2002, 12, 689-692. (Pubitemid 34158924)
51. Seltzman, H.H. Recent CB1 Cannabinoid Receptor Antagonists and Inverse Agonists, Drug Development Research, 2009, 70, 601-615.
52. Rossi, R.; Bellina, F.; Synthesis and biological activity of pyrrole, pyrroline and pyrrolidine derivatives with two aryl groups on adjacent positions. Tetrahedron, 2006, 62, 7213-56. (Pubitemid 44218981)
53. Khanna, I. K.; Weier, R. M.; Paul, Y. Y.; Collins, W.; Miyashiro, J. M.; Koboldt, C. M.; Veenhuizen, A. W.; Currie, J. L.; Seibert, K.; Isakson, P. C. 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. J. Med. Chem., 1997, 40, 1619-1633. (Pubitemid 27231465)
54. Ushiyama, S.; Yamada, T.; Murakami, Y.; Kumakura, S.; Inoue, S.; Suzuki, K.; Nakao, A.; Kawara, A.; Kimura, T. Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects, Eur. J. Pharmacol., 2008, 578, 76-86. (Pubitemid 350179749)
55. Gierse, J.K.; Zhang, Y.; Hood, W.F.; et al., Valdecoxib: Assessment of cyclooxygenase-2 potency and selectivity J. Pharmacol. Exp. Ther, 2005, 312, 1206-12. (Pubitemid 40293782)
56. Esser, R.; Berry, C.; Du, Z.; et al. Preclinical pharmacology of lumiracoxib: A novel selective inhibitor of cyclooxygenase-2. Br. J. Pharmacol., 2005, 144, 538-50. (Pubitemid 40349461)
57. Khanapure, S.P.; Garvey, D.S.; Young, D.V.; et al. Synthesis and structureactivity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors. J. Med. Chem., 2003, 4, 5484-504. (Pubitemid 37492953)
58. Paramashivappa, R.; Kumar, P.P.; Rao, P. V.S.; Rao, A.S. Design, synthesis and biological evaluation of benzimidazole/benzothiazole and benzoxazole derivatives as cyclooxygenase inhibitors. Bioorg. Med. Chem. Lett., 2003, 13, 657-60. (Pubitemid 36298462)
59. Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dube, D.; Ethier, D. ; Falgueyret, J.-P.; Friesen, R. W.; Gordon, R.; Greig, G.; Guay, I.; Manacini, J.; Ouellet, M.; Wong, E.; Xu, L.; Boyce, S.; Visco, D.; Girad, Y.; Prasit, P.; Zamboni, R.; Rodger, J. W.; Gresser, M.; Ford-Hutchinson, A. W.; Young, R. N.; Chan, C.-C. J. Pharmacol. Exp. Ther., 2001, 296, 558-566.
60. Warner, T.D.; Giuliano, E; Vojnovic, I.; Bukasa, A.; Mitchell, J.A.; Vane, J.R.. Nonsteroid drug selectivltles for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis: Proc. Natl Acad. Sci., 1999, 96, 7563-8. (Pubitemid 29299702)
61. Tegeder, I.; LÖtsch, J.; Krebs, S.; Muth-Selbach, U.; Brune, K.; Geisslinger, G. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin. Pharmacol. Ther., 1999, 65(5), 533-44. (Pubitemid 29237327)
62. Rimon, G.; Sidhu, R.S.; Lauver, D.A.; Lee, Y.J.; Sharma, N.P.; Yuan, C.; Frieler, R.A.; Trievel, R.C.; Lucchesi, B.R.; Smith, W.L. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc. Natl. Acad. Sci. USA, 2010, 107, 28-33.
63. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural Basis for Selective Inhibition of Cyclooxygenase-2 by Anti-inflammatory Agents. Nature, 1996, 384, 644-48.